Epstein-Barr virus nuclear antigen 2, 3A, 3B, 3C, LP, and BARF0-derived peptide-MHC complexes (EBV EBNA/BARF0 pMHC)

Epstein-Barr virus (EBV) nuclear antigens (EBNA2, 3A, 3B, 3C, LP) and the BARF0 protein are essential components of the EBV latent cycle, primarily involved in the immortalization and transformation of host B-lymphocytes (Cohen, 2000, NEJM). These proteins act as transcriptional regulators that manipulate host cell pathways to drive proliferation and evade apoptosis (Kempkes & Robertson, 2015, Trends Microbiol). In EBV-associated malignancies, such as post-transplant lymphoproliferative disorder (PTLD) and nasopharyngeal carcinoma, these antigens are processed into short peptides and presented on the cell surface by Major Histocompatibility Complex (MHC) molecules (Taylor et al., 2015, Curr Opin Virol). These peptide-MHC (pMHC) complexes serve as highly specific targets for cytotoxic T lymphocytes (CTLs), which recognize them via T-cell receptors (TCRs) (Heslop et al., 2010, Blood). Therapeutic strategies like tabelecleucel (Ebvallo) utilize allogeneic EBV-specific T-cells to target these pMHC complexes, providing a precision immunotherapy for patients with EBV-driven cancers (Prockop et al., 2020, Ther Adv Hematol). This approach is designed to selectively eliminate malignant cells while minimizing damage to healthy, non-infected tissues (EMA, 2022, Ebvallo SmPC). The efficacy of these therapies depends on the presence of specific HLA alleles that can present the viral peptides to the therapeutic T-cells (Taylor et al., 2015, Curr Opin Virol). Overall, these pMHC complexes represent a critical interface between the virus and the host immune system, offering a viable pathway for treating refractory EBV-related diseases.

Other names

EBV latent antigen peptide-HLA complexesEBNA-2/3A/3B/3C/LP/BARF0 pMHCEpstein-Barr virus latent cycle antigen complexesEBV-specific T-cell targets

T-cell receptor-mediated recognition of viral peptides presented by MHC molecules, leading to the targeted destruction of EBV-infected cells.